JATT Acquisition (JATT) Competitors $1.26 -0.09 (-6.64%) As of 03/28/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock JATT vs. SLN, ANIX, MGNX, RENB, XBIT, FATE, NKTX, ORMP, OPTN, and BDTXShould you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Silence Therapeutics (SLN), Anixa Biosciences (ANIX), MacroGenics (MGNX), Renovaro (RENB), XBiotech (XBIT), Fate Therapeutics (FATE), Nkarta (NKTX), Oramed Pharmaceuticals (ORMP), OptiNose (OPTN), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. JATT Acquisition vs. Silence Therapeutics Anixa Biosciences MacroGenics Renovaro XBiotech Fate Therapeutics Nkarta Oramed Pharmaceuticals OptiNose Black Diamond Therapeutics JATT Acquisition (NYSE:JATT) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends, valuation and community ranking. Does the MarketBeat Community believe in JATT or SLN? Silence Therapeutics received 43 more outperform votes than JATT Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformJATT AcquisitionN/AN/ASilence TherapeuticsOutperform Votes4379.63% Underperform Votes1120.37% Which has better earnings and valuation, JATT or SLN? JATT Acquisition has higher earnings, but lower revenue than Silence Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/ASilence Therapeutics$43.26M2.38-$53.82M-$0.95-3.62 Do institutionals and insiders believe in JATT or SLN? 48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is JATT or SLN more profitable? JATT Acquisition has a net margin of 0.00% compared to Silence Therapeutics' net margin of -342.00%. JATT Acquisition's return on equity of -49.58% beat Silence Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% Silence Therapeutics -342.00%-62.81%-33.89% Do analysts recommend JATT or SLN? Silence Therapeutics has a consensus price target of $40.67, indicating a potential upside of 1,082.17%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than JATT Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Does the media favor JATT or SLN? In the previous week, Silence Therapeutics had 3 more articles in the media than JATT Acquisition. MarketBeat recorded 3 mentions for Silence Therapeutics and 0 mentions for JATT Acquisition. Silence Therapeutics' average media sentiment score of 1.08 beat JATT Acquisition's score of 0.00 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment JATT Acquisition Neutral Silence Therapeutics Positive SummarySilence Therapeutics beats JATT Acquisition on 8 of the 13 factors compared between the two stocks. Remove Ads Get JATT Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JATT vs. The Competition Export to ExcelMetricJATT AcquisitionBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$21.82M$3.03B$5.63B$19.39BDividend YieldN/A1.55%5.33%3.76%P/E RatioN/A30.4523.6033.06Price / SalesN/A431.82388.2326.59Price / Cash27.08168.6838.1717.55Price / Book-2.393.926.894.53Net Income$6.85M-$71.95M$3.20B$1.02B7 Day Performance-8.99%-5.68%-3.06%-1.30%1 Month Performance2.02%-12.09%1.52%-4.04%1 Year Performance-50.78%-27.90%9.37%2.55% JATT Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JATTJATT AcquisitionN/A$1.27-6.6%N/A-50.8%$21.82MN/A0.003High Trading VolumeSLNSilence Therapeutics2.2462 of 5 stars$3.40-6.2%$40.67+1,097.8%-84.1%$101.61M$43.26M-2.16100Positive NewsANIXAnixa Biosciences3.1272 of 5 stars$3.15-0.2%$9.00+186.2%-4.8%$101.26M$210,000.00-8.065Analyst ForecastAnalyst RevisionNews CoveragePositive NewsMGNXMacroGenics3.8872 of 5 stars$1.61-9.9%$7.38+357.5%-91.4%$101.24M$148.34M-1.02430Analyst ForecastAnalyst RevisionRENBRenovaro1.0624 of 5 stars$0.63-5.1%N/A-78.1%$100.15MN/A-0.6820Positive NewsGap DownXBITXBiotech1.2367 of 5 stars$3.25-1.7%N/A-61.9%$98.93M$4.01M-3.00100Short Interest ↓Positive NewsGap UpFATEFate Therapeutics3.8705 of 5 stars$0.86-4.7%$5.50+539.5%-88.4%$98.55M$13.63M-0.52550Positive NewsNKTXNkarta2.627 of 5 stars$1.34-6.6%$15.00+1,023.6%-81.5%$94.21MN/A-0.71140Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageORMPOramed Pharmaceuticals1.5376 of 5 stars$2.32-0.4%N/A-24.3%$93.52M$1.34M21.0910Earnings ReportPositive NewsOPTNOptiNose2.7311 of 5 stars$9.16-0.2%$9.00-1.7%-58.2%$92.10M$75.67M-2.18190Earnings ReportBDTXBlack Diamond Therapeutics3.3841 of 5 stars$1.63-3.8%$14.60+798.5%-68.2%$92.08MN/A-1.2290 Remove Ads Related Companies and Tools Related Companies SLN Alternatives ANIX Alternatives MGNX Alternatives RENB Alternatives XBIT Alternatives FATE Alternatives NKTX Alternatives ORMP Alternatives OPTN Alternatives BDTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:JATT) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JATT Acquisition Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share JATT Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
